Summary | |
---|---|
Symbol | CTSG |
Name | cathepsin G |
Aliases | CG; CATG |
Chromosomal Location | 14q12 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cell surface |
Domain |
PF00089 Trypsin |
Function |
Serine protease with trypsin- and chymotrypsin-like specificity. Cleaves complement C3. Has antibacterial activity against the Gram-negative bacterium P.aeruginosa, antibacterial activity is inhibited by LPS from P.aeruginosa, Z-Gly-Leu-Phe-CH2Cl and phenylmethylsulfonyl fluoride. |
Biological Process |
GO:0001906 cell killing GO:0001909 leukocyte mediated cytotoxicity GO:0001990 regulation of systemic arterial blood pressure by hormone GO:0001991 regulation of systemic arterial blood pressure by circulatory renin-angiotensin GO:0002002 regulation of angiotensin levels in blood GO:0002003 angiotensin maturation GO:0002237 response to molecule of bacterial origin GO:0002443 leukocyte mediated immunity GO:0002444 myeloid leukocyte mediated immunity GO:0002446 neutrophil mediated immunity GO:0003013 circulatory system process GO:0003044 regulation of systemic arterial blood pressure mediated by a chemical signal GO:0003073 regulation of systemic arterial blood pressure GO:0003081 regulation of systemic arterial blood pressure by renin-angiotensin GO:0008015 blood circulation GO:0008217 regulation of blood pressure GO:0009620 response to fungus GO:0010817 regulation of hormone levels GO:0016485 protein processing GO:0016486 peptide hormone processing GO:0022617 extracellular matrix disassembly GO:0030198 extracellular matrix organization GO:0031640 killing of cells of other organism GO:0032496 response to lipopolysaccharide GO:0035821 modification of morphology or physiology of other organism GO:0042445 hormone metabolic process GO:0042742 defense response to bacterium GO:0043062 extracellular structure organization GO:0043900 regulation of multi-organism process GO:0043901 negative regulation of multi-organism process GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism GO:0044110 growth involved in symbiotic interaction GO:0044116 growth of symbiont involved in interaction with host GO:0044117 growth of symbiont in host GO:0044126 regulation of growth of symbiont in host GO:0044130 negative regulation of growth of symbiont in host GO:0044144 modulation of growth of symbiont involved in interaction with host GO:0044146 negative regulation of growth of symbiont involved in interaction with host GO:0044364 disruption of cells of other organism GO:0045926 negative regulation of growth GO:0050830 defense response to Gram-positive bacterium GO:0050832 defense response to fungus GO:0050886 endocrine process GO:0051604 protein maturation GO:0051702 interaction with symbiont GO:0051817 modification of morphology or physiology of other organism involved in symbiotic interaction GO:0051818 disruption of cells of other organism involved in symbiotic interaction GO:0051851 modification by host of symbiont morphology or physiology GO:0051852 disruption by host of symbiont cells GO:0051873 killing by host of symbiont cells GO:0051883 killing of cells in other organism involved in symbiotic interaction GO:0060177 regulation of angiotensin metabolic process GO:0070942 neutrophil mediated cytotoxicity GO:0070943 neutrophil mediated killing of symbiont cell GO:0070944 neutrophil mediated killing of bacterium GO:0070946 neutrophil mediated killing of gram-positive bacterium GO:0098542 defense response to other organism |
Molecular Function |
GO:0004175 endopeptidase activity GO:0004252 serine-type endopeptidase activity GO:0005539 glycosaminoglycan binding GO:0008201 heparin binding GO:0008236 serine-type peptidase activity GO:0017171 serine hydrolase activity GO:1901681 sulfur compound binding |
Cellular Component |
GO:0030141 secretory granule GO:0099503 secretory vesicle |
KEGG |
hsa04080 Neuroactive ligand-receptor interaction hsa04142 Lysosome hsa04614 Renin-angiotensin system |
Reactome |
R-HSA-1592389: Activation of Matrix Metalloproteinases R-HSA-6803157: Antimicrobial peptides R-HSA-1474228: Degradation of the extracellular matrix R-HSA-1474244: Extracellular matrix organization R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-2022377: Metabolism of Angiotensinogen to Angiotensins R-HSA-392499: Metabolism of proteins R-HSA-6798695: Neutrophil degranulation R-HSA-2980736: Peptide hormone metabolism R-HSA-381426: Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) |
Summary | |
---|---|
Symbol | CTSG |
Name | cathepsin G |
Aliases | CG; CATG |
Chromosomal Location | 14q12 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between CTSG and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between CTSG and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | CTSG |
Name | cathepsin G |
Aliases | CG; CATG |
Chromosomal Location | 14q12 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of CTSG in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | CTSG |
Name | cathepsin G |
Aliases | CG; CATG |
Chromosomal Location | 14q12 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of CTSG in various data sets.
|
Points in the above scatter plot represent the mutation difference of CTSG in various data sets.
|
Summary | |
---|---|
Symbol | CTSG |
Name | cathepsin G |
Aliases | CG; CATG |
Chromosomal Location | 14q12 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CTSG. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | CTSG |
Name | cathepsin G |
Aliases | CG; CATG |
Chromosomal Location | 14q12 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CTSG. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CTSG. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | CTSG |
Name | cathepsin G |
Aliases | CG; CATG |
Chromosomal Location | 14q12 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CTSG. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | CTSG |
Name | cathepsin G |
Aliases | CG; CATG |
Chromosomal Location | 14q12 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of CTSG expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | CTSG |
Name | cathepsin G |
Aliases | CG; CATG |
Chromosomal Location | 14q12 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between CTSG and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | CTSG |
Name | cathepsin G |
Aliases | CG; CATG |
Chromosomal Location | 14q12 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting CTSG collected from DrugBank database. |
Details on drugs targeting CTSG.
|